Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Raymond Mak

Radiation Oncology Boston, MA Medical Doctor

NPI 1285784041 CMS profile 542921

75 Francis St, Asb1-L2, Radiation Oncology, Brigham & Women's Hospital, Boston, MA 02115

Open in the dashboard

General payments

$36,167

25 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$172,251 paid to institutions, not to them · program years 2020–2022

Through program year 2025, Raymond Mak of Boston, MA is reported in the CMS Open Payments database as having received $36,167 across 25 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $172,251 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,500 1
2024 General $10,724 3
2023 General $13 1
2022 General $8,326 9
2021 General $7,553 6
2020 General $7,052 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Mak
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Raymond Mak were reported at $2,500. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Raymond Mak Radiation Oncology median Middle half National median
2019 $0 $138 $48–$462 $163
2020 $7,052 $79 $26–$262 $114
2021 $7,553 $119 $37–$358 $132
2022 $8,326 $139 $43–$424 $149
2023 $13 $167 $57–$473 $160
2024 $10,724 $168 $56–$541 $164
2025 $2,500 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $14,877 5 payments
  2. Viewray Technologies Inc $14,478 16 payments
  3. Novartis Pharmaceuticals Corporation $3,300 1 payment
  4. Pfizer Inc. $2,500 1 payment
  5. Siemens Medical Solutions USA, Inc. $1,013 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $21,182 10 payments
  2. Honoraria $6,600 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,900 5 payments
  4. Travel and Lodging $2,073 2 payments
  5. Food and Beverage $413 4 payments
Products named General payments · program years 2020–2025
  1. IMFINZI $7,551 3 payments
  2. MRIdian Radiotherapy $7,052 5 payments
  3. MRIdian LINAC $4,026 7 payments
  4. MRIdian Radiotherapy $3,400 4 payments
  5. ILARIS $3,300 1 payment
  6. LORBRENA $2,500 1 payment
  7. TrueBeam $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$139,724

Medicare's payments for the services billed

Medicare patients

229

Average age 76

Services billed

1,552

116 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 39%
COPD 38%
Chronic kidney disease 36%
Ischemic heart disease 35%
Atrial fibrillation 30%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $3,398
$3,398 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record